RRx-007

RRx-007 is a small molecule therapeutic candidate developed by EpicentRx, Inc. for the treatment of solid tumors. It is part of the company's proprietary RRx platform, which focuses on the development of redox-active compounds that modulate the tumor microenvironment and overcome treatment resistance. While specific molecular targets for RRx-007 are not publicly disclosed, the RRx class of drugs typically functions by inducing oxidative stress, inhibiting aerobic glycolysis (the Warburg effect), and sensitizing tumors to conventional therapies like chemotherapy and radiation. RRx-007 is currently being evaluated in Phase 1 clinical trials to determine its safety, tolerability, and preliminary efficacy in patients with advanced solid malignancies.